Literature DB >> 16787846

Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

C C Chiueh1, T Andoh, A R Lai, E Lai, G Krishna.   

Abstract

Brain undergoes neurodegeneration when excess free radicals overwhelm antioxidative defense systems during senescence, head trauma and/or neurotoxic insults. A site-specific accumulation of ferrous citrate-iron complexes in the substantia nigra dopaminergic neurons could lead to exaggerated dopamine turnover, dopamine auto-oxidation, free radical generation, and oxidant stress. Eventually, this iron-catalyzed dopamine auto-oxidation results in the accumulation of neuromelanin, a progressive loss of nigral neurons, and the development of Parkinson's disease when brain dopamine depletion is greater than 80%. Emerging evidence indicates that free radicals such as hydroxyl radicals ((.-)OH) and nitric oxide ((.-)NO) may play opposite role in cell and animal models of parkinsonism. (.-)OH is a cytotoxic oxidant whereas oNO is an atypical neuroprotective antioxidant. (.-)NO and S-nitrosoglutathione (GSNO) protect nigral neurons against oxidative stress caused by 1-methyl-4-phenylpyridinium (MPP(+)), dopamine, ferrous citrate, hemoglobin, sodium nitroprusside and peroxynitrite. MPP(+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), increases the nigral uptake of iron complexes and dopamine overflow leading to the generation of (.-)OH, protein oxidation, lipid peroxidation, and associated retrograde degeneration. In addition to GSNO, MPP(+)-induced oxidative neurotoxicity can be prevented by antioxidants including selegiline, 7-nitroindazole, 17beta-estradiol, melatonin, alpha-phenyl-tert-butylnitrone and U78517F. Similar to selegiline, 7-nitroindazole is a MAO-B inhibitor, which blocks the bio-activation of MPTP and oxidative stress. Freshly prepared but not light exposed, (.-)NO-exhausted GSNO is about 100 times more potent than the classic antioxidant glutathione. Via S-nitrosylation, GSNO also inhibits proteolysis and cytotoxicity caused by caspases and HIV-1 protease. Furthermore, in addition to protection against serum deprivation stress, the induction of neuronal NOS1 in human cells increases tolerance to MPP(+)-induced neuro-toxicity since newly synthesized (.-)NO prevents apoptosis possibly through up-regulation of bcl-2 and down regulation of p66(shc). In conclusion, reactive oxygen species are unavoidable by-products of iron-catalyzed dopamine auto-oxidation, which can initiate lipid peroxidation, protein oxidation, DNA damage, and nigral loss, all of which can be prevented by endogenous and exogenous (.-)NO. Natural and man-made antioxidants can be employed as part of preventative or neuroprotective treatments in Parkinson's disease and perhaps dementia complexes as well. For achieving neuroprotection and neuro-rescue in early clinical parkinsonian stages, a cocktail therapy of multiple neuroprotective agents may be more effective than the current treatment with extremely high doses of a single antioxidative agent.

Entities:  

Year:  2000        PMID: 16787846     DOI: 10.1007/bf03033799

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  142 in total

1.  Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus.

Authors:  H Lahtinen; J Koistinaho; R Kauppinen; A Haapalinna; R Keinänen; J Sivenius
Journal:  Brain Res       Date:  1997-05-23       Impact factor: 3.252

2.  Kynostatin and 17beta-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease.

Authors:  V Hawkins; Q Shen; C C Chiueh
Journal:  J Biomed Sci       Date:  1999 Nov-Dec       Impact factor: 8.410

Review 3.  Manganese neurotoxicity: a mechanistic hypothesis.

Authors:  M A Verity
Journal:  Neurotoxicology       Date:  1999 Apr-Jun       Impact factor: 4.294

4.  Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity.

Authors:  R M Wu; D L Murphy; C C Chiueh
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity.

Authors:  R T Matthews; L Yang; M F Beal
Journal:  Exp Neurol       Date:  1997-02       Impact factor: 5.330

6.  MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN).

Authors:  A Fredriksson; P Eriksson; T Archer
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Peroxidation of brain lipids in vitro: nitric oxide versus hydroxyl radicals.

Authors:  P Rauhala; I Sziraki; C C Chiueh
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

8.  Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline).

Authors:  R M Wu; D L Murphy; C C Chiueh
Journal:  Ann N Y Acad Sci       Date:  1996-06-15       Impact factor: 5.691

9.  Sustained release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats.

Authors:  A Ogata; K Nagashima; K Yasui; T Matsuura; K Tashiro
Journal:  J Neurol Sci       Date:  1998-08-14       Impact factor: 3.181

10.  Induction of NADPH-diaphorase activity in the hippocampus in a rat model of cerebral ischemia and ischemic tolerance.

Authors:  H Kato; K Kogure; Y Liu; T Araki; Y Itoyama
Journal:  Brain Res       Date:  1994-07-25       Impact factor: 3.252

View more
  24 in total

1.  S-Nitrosoglutathione administration ameliorates cauda equina compression injury in rats.

Authors:  Anandakumar Shunmugavel; Mushfiquddin Khan; Marcus M Martin; Anne G Copay; Brian R Subach; Thomas C Schuler; Inderjit Singh
Journal:  Neurosci Med       Date:  2012-09-25

2.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

3.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 5.  Brain oxidative stress as basic target of antioxidant traditional oriental medicines.

Authors:  Tetsuya Konishi
Journal:  Neurochem Res       Date:  2008-11-06       Impact factor: 3.996

6.  Association between neonatal iron overload and early human brain development in premature infants.

Authors:  Sanjiv B Amin; Gary Myers; Hongyue Wang
Journal:  Early Hum Dev       Date:  2012-02-18       Impact factor: 2.079

Review 7.  S-glutathionylation: from molecular mechanisms to health outcomes.

Authors:  Ying Xiong; Joachim D Uys; Kenneth D Tew; Danyelle M Townsend
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

Review 8.  New strategies in neuroprotection and neurorepair.

Authors:  Marta C Antonelli; Gilles J Guillemin; Rita Raisman-Vozari; Elaine A Del-Bel; Michael Aschner; Michael A Collins; Yousef Tizabi; Rosario Moratalla; Adrian K West
Journal:  Neurotox Res       Date:  2011-08-23       Impact factor: 3.911

Review 9.  Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity.

Authors:  Vittorio Calabrese; Carolin Cornelius; Cesare Mancuso; Giovanni Pennisi; Stella Calafato; Francesco Bellia; Timothy E Bates; Anna Maria Giuffrida Stella; Tony Schapira; Albena T Dinkova Kostova; Enrico Rizzarelli
Journal:  Neurochem Res       Date:  2008-07-16       Impact factor: 3.996

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.